Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | PTGES | O14684 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | VCP | P55072 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | MAOB | P27338 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660072 | 1.00 | RAB9A (0.67) | RAB9ANPC1ARGSTO1MEN1 | |
| SCHEMBL3598628 | 0.84 | MAPT (0.58) | RAB9ANPC1GSTO1MEN1KMT2A | |
| SCHEMBL3603436 | 0.84 | MEN1 (0.61) | RAB9ANPC1GSTO1MEN1KMT2A | |
| SCHEMBL3615155 | 0.83 | ALOX5 (0.51) | RAB9ANPC1GSTO1MEN1KMT2A | |
| SCHEMBL13578656 | 0.83 | MEN1 (0.59) | RAB9ANPC1GSTO1MEN1KMT2A | |
| Bromide SCHEMBL7330009 | 0.82 | MEN1 (0.59) | RAB9ANPC1GSTO1MEN1KMT2A | |
| SCHEMBL4333461 | 0.82 | RAB9A (0.53) | RAB9ANPC1GSTO1MEN1KMT2A | |
| SCHEMBL30581066 | 0.82 | RAB9A (0.78) | RAB9ANPC1ARGSTO1MEN1 | |
| SCHEMBL3597550 | 0.82 | RRM1 (0.64) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL2380037 | 0.81 | RAB9A (0.61) | RAB9ANPC1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | RAB9A 1024/4885NPC1 267/4885AR 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.